Aging Into Medicare Tied to Higher Drug Costs for People With Diabetes
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 17, 2024 -- As people with diabetes age into Medicare, they face increased quarterly out-of-pocket costs for medication, according to a study published online July 9 in JAMA Network Open.
Douglas Barthold, Ph.D., from the University of Washington in Seattle, and colleagues examined whether reaching age 65 years is associated with changes in type 2 diabetes (T2D) medication out-of-pocket costs and utilization. The analysis included seven years of prescription drug claims data for 129,997 individuals with T2D identified from the TriNetX Diamond Network (before and after turning 65 years).
The researchers found that reaching age 65 years was associated with an increase of $23.04 in mean quarterly out-of-pocket costs for T2D drugs, including an increase of $56.36 at the 95th percentile of spending, after utilization adjustment. At age 65 years, utilization decreased by 5.3 percent (3.40 claims per quarter to 3.22 claims per quarter). A shift in utilization composition showed increased insulin use, which was associated with additional increases in patient costs.
"The increased patient cost burden at age 65 years and a modest reduction in overall T2D drug utilization suggest that as people with T2D age into Medicare, there is potentially an increase in nonadherence and diabetes complications," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Adding Depression, Anxiety Measures to CVD Prediction Model Has Little Impact
MONDAY, Jan. 13, 2025 -- Inclusion of measures of depression and anxiety to the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) prediction...
Polypill Treatment Offers High Value in Low-Income, Underserved Population
MONDAY, Jan. 13, 2025 -- Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to a study published online...
MEK Inhibition Beneficial for Children With Subset of Severe Hypertrophic Cardiomyopathy
MONDAY, Jan. 13, 2025 -- For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.